AbbVie vs Talphera
AbbVie (ABBV) and Talphera (TLPH) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $506B
- Last close
- $286.20
- 12 months
- +24.7%
- Market value
- $40.8M
- Last close
- $0.7852
- 12 months
- −40.1%
At a glance
- By market value, AbbVie ($505.9B) is about 12400 times Talphera ($41M).
- Over the last 12 months AbbVie's share price moved +24.7% and Talphera's −40.1%; against the S&P 500 that is +19.0 points and −45.8 points.
- In their last fiscal years AbbVie kept 6.9% of revenue as net income and Talphera -51035.7%.
- In the last 90 days insiders reported 0 open-market purchases at AbbVie and 0 at Talphera; members of Congress disclosed 1 trade in AbbVie and 0 in Talphera.
- Next results: AbbVie Feb 2, 2027, Talphera Mar 22, 2027.
Share prices on one chart
AbbVie and Talphera, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| AbbVie ABBVNYSE · Pharmaceuticals | Talphera TLPHNASDAQ · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $506B | $40.8M |
| Revenue, last fiscal year | $61.2B | $28K |
| Net income, last fiscal year | $4.23B | −$14.3M |
| Net marginNet income as a share of revenue | 6.9% | -51035.7% |
| Free cash flow | $17.8B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
AbbVie against
Common questions
How is AbbVie different from Talphera?
AbbVie (ABBV) is in Pharmaceuticals on NYSE, with $61.2B of revenue in its last fiscal year and a net margin of 6.9%. Talphera (TLPH) is in Pharmaceutical Preparations on NASDAQ, with $28K of revenue in its last fiscal year and a net margin of -51035.7%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do AbbVie and Talphera compare in size?
AbbVie has the larger market value: AbbVie $506B and Talphera $40.8M, at the last close.
Whose share price rose more over the last 12 months, ABBV or TLPH?
Over the last 12 months AbbVie moved +24.7% and Talphera −40.1%. Past price moves say nothing about the future.
Which has had more insider buying, AbbVie or Talphera?
Since 2006, Talphera insiders reported 98 open-market purchases against 25 for AbbVie. These are counts of what was filed, not a view on either stock.
Do members of Congress trade ABBV or TLPH?
In the last 12 months, members of Congress disclosed 9 trades in AbbVie (ABBV) and 0 in Talphera (TLPH).
When did insiders last buy ABBV and TLPH?
AbbVie: Mar 30, 2020. Talphera: Feb 21, 2026.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
AbbVie pageTalphera pageRare insider trades this weekAll comparisons
https://oqro.io/compare/abbv-vs-tlph







